Key result
Three recent trials (TACTICS-TIMI 18, ADMIRAL, and TARGET) provide new information about the relative merits of pharmacologic therapy and percutaneous coronary intervention in acute coronary syndromes.
This editorial discusses the evolving strategies for the optimal treatment of acute coronary syndromes based on the findings of the TACTICS-TIMI 18, ADMIRAL, and TARGET trials.
The management of acute coronary syndromes has evolved rapidly over the past decade and continues to do so. Three studies on this topic appear in this issue of the Journal. They are the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy–Thrombolysis in Myocardial Infarction 18 (TACTICS–TIMI 18) trial,1 the Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up (ADMIRAL) trial,2 and the Do Tirofiban and ReoPro Give Similar Efficacy Trial (TARGET).3 All three provide new information about the relative merits of pharmacologic therapy and percutaneous coronary intervention, . . .
No takes yet. Share an insight, caveat, or question.
Boden et al. (2001) conducted an editorial in Acute coronary syndromes. Pharmacologic therapy and percutaneous coronary intervention was evaluated. Three recent trials (TACTICS-TIMI 18, ADMIRAL, and TARGET) provide new information about the relative merits of pharmacologic therapy and percutaneous coronary intervention in acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: